Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for about $63 billion, grabbing control of by far the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira.
Latest posts by Reuters News (see all)
- ‘So far so good’, says Trump after G7 arrival - August 24, 2019
- Indian opposition leaders denied entry to Kashmir, sent back from airport - August 24, 2019
- China warns U.S. to stop ‘wrong’ trade actions or face consequences - August 24, 2019